CDC181 as A Cancer Drug Target (G57821)

Target Name: CCDC181

NCBI ID: G57821

CCDC181

CDC181 as A Cancer Drug Target

CCDC181 (CC181_HUMAN), a protein that belongs to the C-type water-soluble Superfamily, is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer. The protein is expressed in various tissues and organs of the human body, including the brain, heart, kidneys, and liver.

One of the key features of CCDC181 is its role in the regulation of cell growth and differentiation. It is a key regulator of the Wnt signaling pathway, a pathway that plays a crucial role in the development and maintenance of tissues and organs. Wnt signaling is a highly conserved signaling pathway that is involved in many diseases, including cancer.

Research has shown that changes in the expression of CCDC181 can have a significant impact on the development and progression of various diseases, including cancer. For example, studies have shown that high levels of CCDC181 expression are associated with poor prognosis in patients with pancreatic cancer, and that reducing CCDC181 expression can improve survival in these patients.

Another potential mechanism by which CCDC181 may contribute to the development and progression of cancer is its role in cell migration. Research shows that CCDC181 is involved in the regulation of cell migration and the ability of cells to move from one location to another. This is important for the development of new tumors, as cancer cells are able to move from the primary tumor to other parts of the body to establish new colonies.

In addition to its role in cell growth and differentiation, CCDC181 has also been shown to be involved in the regulation of cellular stress responses. Stress can cause cells to enter a state of division arrest, a process that is important for maintaining tissue homeostasis and preventing disease. Studies have shown that CCDC181 is involved in the regulation of cell stress responses, and that changes in CCDC181 expression can have a significant impact on the ability of cells to respond to stress.

Given its involvement in so many important cellular processes, CCDC181 is a promising target for drug development. Researchers are currently working to develop small molecules and other compounds that can specifically target CCDC181 and modulate its expression to treat various diseases, including cancer.

In conclusion, CCDC181 is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its role in the regulation of cell growth and differentiation, as well as its involvement in cell migration and cellular stress responses, make it an attractive target for drug development. Further research is needed to fully understand the mechanisms by which CCDC181 contributes to disease and to develop effective treatments.

Protein Name: Coiled-coil Domain Containing 181

Functions: Microtubule-binding protein that localizes to the microtubular manchette of elongating spermatids

The "CCDC181 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC181 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets